Pandemic.Pdf.Pdf
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
An Update Review of Globally Reported SARS-Cov-2 Vaccines in Preclinical and Clinical Stages
International Immunopharmacology 96 (2021) 107763 Contents lists available at ScienceDirect International Immunopharmacology journal homepage: www.elsevier.com/locate/intimp Review An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages Hamid Motamedi a, Marzie Mahdizade Ari b, Shirin Dashtbin b, Matin Fathollahi a, Hadi Hossainpour a, Amirhoushang Alvandi a,c, Jale Moradi a, Ramin Abiri a,d,* a Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran b Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran c Medical Technology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran d Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran ARTICLE INFO ABSTRACT Keywords: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the rapidly spreading COVID-19 pandemic COVID-19 in the world. As an effective therapeutic strategy is not introduced yet and the rapid genetic SARS-CoV-2 variations in the virus, there is an emerging necessity to design, evaluate and apply effective new vaccines. An Vaccines acceptable vaccine must elicit both humoral and cellular immune responses, must have the least side effects and the storage and transport systems should be available and affordable for all countries. These vaccines can be classified into different types: inactivated vaccines, live-attenuated virus vaccines, subunit vaccines, virus-like particles (VLPs), nucleic acid-based vaccines (DNA and RNA) and recombinant vector-based vaccines (repli cating and non-replicating viral vector). According to the latest update of the WHO report on April 2nd, 2021, at least 85 vaccine candidates were being studied in clinical trial phases and 184 candidate vaccines were being evaluated in pre-clinical stages. -
Flattening the Curve: 3/9/2020 We’Re All in This Together, Together We Can Stop the Spread and We All Have a Role to Play
3/23/2020 HOW TO DO IT Flattening the Curve: 3/9/2020 We’re all in this together, Together We Can Stop the Spread and we all have a role to play. • Practice social distancing. This means staying at of COVID-19 & Save Lives least six feet away from others. Without social distancing, people who are sick with COVID-19 will likely infect between 2-3 other people, and The COVID-19 pandemic is continuing to expand and affect our the spread of the virus will continue to grow. community. By making some important changes to the way we live • Stay home and away from public places, and interact with one another, we can stop the spread and save lives. especially if you are sick. • Wash your hands frequently with soap and water. • Cover your nose and mouth with a tissue when FLATTENING THE CURVE coughing and sneezing, throw the tissue away and then wash your hands. If the COVID-19 pandemic If we can slow the spread, That’s why public health orders that promote social • Avoid touching your face including your eyes, continues to grow at the just as many people might nose and mouth. current pace, it will eventually get sick, but the distancing are being put in overwhelm our health care added time will allow our place. By flattening the curve • Disinfect frequently touched objects and system, and in-turn, increase health care system to — reducing the number of surfaces, like door knobs and your phone. the number of people who provide lifesaving care to the people who will get experience severe illness or people who need it. -
COVIPENDIUM Aug4.Pdf
COVIPENDIUM Information available to support the development of medical countermeasures and interventions against COVID-19 Cite as: Martine DENIS, Valerie VANDEWEERD, Rein VERBEEKE, Anne LAUDISOIT, Tristan REID, Emma HOBBS, Laure WYNANTS & Diane VAN DER VLIET. (2020). COVIPENDIUM: information available to support the development of medical countermeasures and interventions against COVID-19 (Version 2020-08-04). Transdisciplinary Insights. This document is conceived as a living document, updated on a weekly basis. You can find its latest version at: https://rega.kuleuven.be/if/corona_covid-19. The COVIPENDIUM is based on open-access publications (scientific journals and preprint databases, communications by WHO and OIE, health authorities and companies) in English language. Please note that the present version has not been submitted to any peer-review process. Any comment / addition that can help improve the contents of this review will be most welcome. For navigation through the various sections, please click on the headings of the table of contents and follow the links marked in blue in the document. Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane Van der Vliet COVIPENDIUM version: 04 AUG 2020 Transdisciplinary Insights - Living Paper | 1 Contents List of abbreviations .......................................................................................................................................................... 9 Introduction ................................................................................................................................................................... -
WHO COVID-19 Database Search Strategy (Updated 26 May 2021)
Search purpose: Systematic search of the COVID-19 literature performed Monday through Friday for the WHO Database. Search strategy as of 26 May 2021. Searches performed by Tomas Allen, Kavita Kothari, and Martha Knuth. Use following commands to pull daily new entries: Entry_date:( [20210101 TO 20210120]) Entry_date:( 20210105) Duplicates: Duplicates are found in EndNote and Distillr using the Wichor method. Further screening is done by expert reviewers but some duplicates may still be in the database. Daily Search Strategy: Database Daily Search Strategy Medline (coronavir* OR corona virus* OR corona pandemic* OR betacoronavir* OR covid19 OR covid OR (Ovid) nCoV OR novel CoV OR CoV 2 OR CoV2 OR sarscov2 OR sars2 OR 2019nCoV OR wuhan virus* OR 1946- NCOV19 OR solidarity trial OR operation warp speed OR COVAX OR "ACT-Accelerator" OR BNT162b2 OR comirnaty OR "mRNA-1273" OR CoviShield OR AZD1222 OR Sputnik V OR CoronaVac OR "BBIBP-CorV" OR "Ad26.CoV2.S" OR "JNJ-78436735" OR Ad26COVS1 OR VAC31518 OR EpiVacCorona OR Convidicea OR "Ad5-nCoV" OR Covaxin OR CoviVac OR ZF2001 OR "NVX-CoV2373" OR "ZyCoV-D" OR CIGB 66 OR CVnCoV OR "INO-4800" OR "VIR-7831" OR "UB-612" OR BNT162 OR Soberana 1 OR Soberana 2 OR "B.1.1.7" OR "VOC 202012/01" OR "VOC202012/01" OR "VUI 202012/01" OR "VUI202012/01" OR "501Y.V1" OR UK Variant OR Kent Variant OR "VOC 202102/02" OR "VOC202102/02" OR "B.1.351" OR "VOC 202012/02" OR "VOC202012/02" OR "20H/501.V2" OR "20H/501Y.V2" OR "501Y.V2" OR "501.V2" OR South African Variant OR "B.1.1.28.1" OR "B.1.1.28" OR "B.1.1.248" OR -
Creating the Fastest Economic Recovery
x Chapter 1 Creating the Fastest Economic Recovery The beginning of 2020 ushered in a strong U.S. economy that was delivering job, income, and wealth gains to Americans of all backgrounds. By February 2020, the unemployment rate had fallen to 3.5 percent—the lowest in 50 years— and unemployment rates for minority groups and historically disadvantaged Americans were at or near their lowest points in recorded history. Wages were rising faster for workers than for managers, income and wealth inequality were on the decline, and median incomes for minority households were experienc- ing especially rapid gains. The fruits of this strong labor market expansion from 2017 to 2019 also included lifting 6.6 million people out of poverty, which is the largest three-year drop to start any presidency since the War on Poverty began in 1964. These accomplishments highlight the success of the Trump Administration’s pro-growth, pro-worker policies. The robust state of the U.S. economy in the three years through 2019 led almost all forecasters to expect continued healthy growth through 2020 and beyond. However, in late 2019 and the early months of 2020, the novel coronavirus that causes COVID-19, with origins in the People’s Republic of China, began spreading around the globe and eventually within the United States, causing a pandemic and bringing with it an unprecedented economic and public health crisis. Both the demand and supply sides of the economy suffered sudden and massive shocks due to the pandemic. During the springtime lockdowns aimed at “flattening the curve,” the labor market lost 22.2 million jobs, and the unemployment rate jumped 11.2 percentage points, to 14.7 percent—the largest monthly changes in the series’ histories. -
COVID-19 & the Swedish Conundrum: Part I Why Did Sweden Not Lock
COVID-19 & The Swedish Conundrum: Part I Why did Sweden not lock down? What were they trying to achieve? Prathap Tharyan The world is cautiously trying to emerge from lockdowns People enjoying the sun in Stockholm on April 21, 2020 Jonathan Nackstrand /AFP via Getty images (Business Insider May 4 2020) No Lockdown: Do the Swedes know something the rest of the world does not know? Or are they playing “Russian Roulette” with their “Herd Immunity” strategy? SWEDEN’S RELAXED CORONAVIRUS RESPONSE NO LOCKDOWN IN SWEDEN: A SOCIAL EXPERIMENT IN COMBATING COVID-19 Cafes, bars, restaurants, elementary schools and most businesses, including hair salons and gyms are open and people are allowed to exercise outdoors Parks and public spaces are open Pubs and bars remain open https://edition.cnn.com/2020/04/28/europe/sweden- Photograph: Ali Lorestani/EPA (The Guardian March 23) coronavirus-lockdown-strategy-intl/index.html WHY IS SWEDEN IS ‘DOING NOTHING’? Advice from the Public Health Agency Sweden has recommended good hygiene as part of infection control “Face masks are meant for Sweden’s Public Health Agency healthcare staff and not needed in in does not recommend face masks the community. for the public The best way to protect oneself and others in daily life is to maintain social distancing and good hand hygiene” SWEDISH PUBLIC HEALTH AGENCY RECOMMENDS SOCIAL DISTANCING No large gatherings (50 people max.) Does not apply to schools, public transport, gyms Work from home if possible Keep arms-length distance from others in all public spaces including -
Iran Hopes to Defeat COVID with Home-Grown Crop of Vaccines
Q&A Iran hopes to defeat COVID with home-grown crop of vaccines Iran is one of few Middle Eastern nations to transfer money is restricted, it is difficult with the capacity to develop vaccines. It to buy drugs and medicines. And we have has been doing so in earnest: more than the technology to produce vaccines, so why ten are in development, but little is known not use it? To ensure the safety of Iranians, it about them outside Iran. Nature speaks makes sense to develop a variety of vaccines to Kayhan Azadmanesh, head of the using different research and development virology division at the Pasteur Institute of strategies, as China has done. Iran in Tehran, about the nation’s vaccine landscape. Azadmanesh also advises the Why are Iranian researchers reluctant to Iranian government and is developing publicize their work internationally? vaccines through his spin-off company This could be another effect of the sanctions. Humimmune Biotech. Researchers in Iran might not want to draw too much attention to their work in case they How badly has the pandemic affected Iran? put potential partnerships in jeopardy or they Since January 2020, we’ve had five waves. run the risk of losing access to raw materials. We’re currently experiencing the highest Researchers are also extremely busy number of new cases reported so far, with during the pandemic. But some have started MAJID ASGARIPOUR/WANA VIA REUTERS MAJID ASGARIPOUR/WANA around 40,000 a day, and the most common to share results. In June, the researchers variant we detect is Delta. -
Accelerating Vaccination Against Covid-19
Accelerating vaccination against Covid-19 Press release of the French National Academy of Medicine April 12, 2021 The major challenge in overcoming the current health crisis is to acquire a sufficient herd immunity to control the circulation of SARS-CoV-2 and to consider the relaxation of restriction measures. Two factors contribute to this collective immunity: the proportion of people who have been infected since the beginning of the pandemic, estimated at 20% of the French population, and the vaccination coverage, which has just exceeded 18% of adults for the first injection. Post-infectious immunity is based on neutralizing antibodies that persist for more than one year after a moderate or severe form of Covid-19, and 6 to 8 months after an asymptomatic form [1], but also on the cellular response of T lymphocytes. This observation has led the French High Authority for Health to recommend that vaccination of immunocompetent individuals with confirmed SARS-CoV-2 infection be delayed for 3 to 6 months after the infectious episode and reduced to a single dose [2]. The vaccination coverage rate to reach the control of the epidemic has been increased to take into account the increased transmissibility of the B.1.1.7 variant, known as "British", which has become predominant throughout metropolitan France. According to the Pasteur Institute's modelling, more than 90% of the adult population would need to be vaccinated to achieve this objective, as long as the vaccination of children is not foreseen [3]. These estimates reinforce the prospect of a sustained circulation of SARS-CoV-2, which may lead to the emergence of new variants, with deleterious consequences on public health and the country's economy. -
MRC Centre for Outbreak Analysis and Modelling
Centre for Outbreak Analysis and Modelling MRC Centre for ANNUAL REPORT Outbreak Analysis and Modelling www.imperial.ac.uk/medicine/outbreaks 2012 The Centre specialises in quantitative epidemiology encompassing mathematical modelling, statistical analysis and evolutionary epidemiology, to aid the control and Director’s message treatment of infectious diseases. April 2013 sees the Centre renewed for a second 5-year Consortium (led by Tim Hallett) and the Vaccine Modelling term, after we received an unprecedented 10 out of 10 Initiative – are up for renewal. However, grants are only score from the MRC subcommittee, which assessed the one aspect of the relationship. As important are the close performance of the Centre over its first term. Just as the working relationships between staff in the Centre and the work of the Centre over that time has been very much a Foundation, which sees our research increasingly used to team effort, so was the success of the renewal. inform Foundation strategy and delivery. The last few months have seen us start to drive through Despite its title, the Centre’s mission rapidly evolved to our strategy for the next 5 years. A crucial aspect of this encompass delivering innovative epidemiological analysis is to boost capacity in key research areas. It is therefore not only of novel infectious disease outbreaks, but also of my pleasure to welcome new academic staff into the endemic diseases of major global health significance. Our Centre. Xavier Didelot joined us last year as a lecturer in work on polio, malaria and HIV reflects this. However, the pathogen genetics, and our expertise in evolutionary and last few months have highlighted the ongoing relevance of genetic research will be further boosted this year by the our original mission to enhance preparedness and response recruitment of at least one additional member of academic to emerging disease threats. -
The Economics of a Pandemic: the Case of Covid-19
The economics of a pandemic: the case of Covid-19 Paolo Surico and Andrea Galeotti Professors of Economics at London Business School london.edu Financial support from the European Research Council and the Wheeler Institute is gratefully acknowledged. This Lecture 1. Science 2. Health policies 3. Economics 4. Macroeconomic policies london.edu The economics of a pandemic: The case of Covid-19 2 The enemy Source: The Economist, 14th March 2020 london.edu The economics of a pandemic: The case of Covid-19 3 The basics about Covid-19: what it is • The cause: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) • The disease: Coronavirus disease 2019 (COVID-19) • Possible origin in wet animal market in Wuhan, China, early Dec 2019 • A strain of the same virus as SARS-CoV-1, which affected 8,000 people in 2002/03 • 96% DNA match between bat coronavirus and human found in a study from February; suggests link to humans is not direct but through intermediate host • Initially pangolins were suspected, but now seems to not be so; still unclear • Made of 4 proteins and a strand of RNA (molecule which can store genetic information) • One protein is the spike, which gives the crown-like appearance • Two proteins sit in the membrane between the spikes to provide structural integrity • In the membrane, the fourth protein is a scaffold around the genetic material Source: The Economist, 23rd January 2020; Nature: “Mystery deepens over animal source of coronavirus” https://www.nature.com/articles/d41586-020-00548-w london.edu The economics of a pandemic: The case of Covid-19 4 The basics about Covid-19: how it works • Enters through nose, mouth, or eyes. -
News in Focus FEI/NYT/REDUX/EYEVINE SLAM YIK Paramedics Transport a Man Thought to Be the First Person in Hong Kong to Have Contracted the New Coronavirus
The world this week News in focus FEI/NYT/REDUX/EYEVINE SLAM YIK Paramedics transport a man thought to be the first person in Hong Kong to have contracted the new coronavirus. WHAT SCIENTISTS WANT TO KNOW ABOUT THE CORONAVIRUS OUTBREAK Researchers have sequenced the deadly pathogen’s genome — and are now rushing to find out how it spreads and how deadly it is. By Ewen Callaway and David Cyranoski Researchers fear similarities to the 2002–03 international concern — the agency’s highest epidemic of severe acute respiratory syn- level of alarm — after a meeting of officials last he world is racing to learn more about drome (SARS), which emerged in southern week, but that could change. the outbreak of a new viral infection that China and killed 774 people in 37 countries. Nature rounds up the questions at the heart was first detected in Wuhan, China, last Both are members of a large virus family, called of scientists’ efforts to understand the virus. month and is causing increasing alarm coronaviruses, that also includes viruses around the world. responsible for the common cold. How does the virus spread? TAs Nature went to press, officials in China China has taken unprecedented action to try This is the most urgent question surrounding had confirmed more than 4,500 cases of the to halt the outbreak — including putting Wuhan the outbreak. Chinese authorities have con- virus, which causes a respiratory illness, and and nearby cities on ‘lockdown’, restricting firmed that it spreads from person to person some 100 deaths. Around 50 cases had also travel in and out of the cities. -
Special Edition - 5Th UPDATE 05/03/21
IMMUNOWATCH Special edition - 5Th UPDATE 05/03/21 COVID-19 INTRODUCTION MabDesign and the COVID-19 pandemic The COVID-19 pandemic was matched by an unprecedented mobilisation of the French immunotherapy network and the pharmaceutical industry at large. Indeed, at the time of publication, three French companies already have preventive and/or therapeutic candidates currently undergoing Phase III clinical trials. In parallel, several bioprocessing sites across France have secured contracts for the production of both drugs and vaccines against SARS-CoV-2. These tremendous results were made possible through accelerated R&D as well as production and distribution logistics combined with facilitated access to information, resources and potential collaborators. MabDesign has been continuously adapting its actions and services to further support and enhance this nationwide pandemic response. Our latest and ongoing contribution to the fight against COVID-19 is through this special edition of Immunowatch and its regular updates. MabDesign’s Immunowatch is a one-of-a-kind information monitoring newsletter in the field of biomedicaments which aims at providing members of our association with the most recent and relevant data gathered or generated through the key expertise of MabDesign and its collaborators in scientific research, business intelligence, market analysis and intellectual property. Its original format has been modified to cater for the fast evolution of the response to the COVID-19 pandemic and allow rapid and pertinent updates. Immunowatch is done in collaboration with the MAbMapping Unit of the Ambition Recherche & Développement (ARD) Biomédicaments 2020 Phase II programme, funded by the Centre Val de Loire region. 2 Table of content 4.